UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1726, 2025

Anteris Technologies Global Corp.

(Exact name of registrant as specified in its charter)

Delaware	001-42437	99-1407174
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Toowong Tower, Level 3, Suite 302 9 Sherwood Road Toowong, QLD Australia		4066
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: +61 7 3152 3200

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		AVR		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 71.0102. ~~Regulation~~Termination FDof ~~Disclosure~~a Material Definitive Agreement.

On November 1626, 2025 ~~(November 17~~, ~~2025 AEDT),~~ Anteris Technologies Global Corp. (the “Company”) ~~issued~~notified an4C ~~ASX~~Medical ~~Announcement~~Technologies, ~~and~~Inc. on(“4C”) ~~November~~that ~~17,~~it ~~2025~~was not renewing the Second Amended and ~~issued~~Restated aSupply ~~press~~and ~~release~~License ~~presenting~~Agreement, as amended (the ~~30-day~~“Supply ~~clinical~~Agreement”), ~~outcomes~~between the Company and 4C, which provided for the ~~DurAVR®~~supply ~~Transcatheter~~by ~~Heart~~the ~~Valve~~Company ~~(THV)~~to 4C of ADAPT® tissue used in ~~one~~4C’s ~~hundred~~production ~~severe~~of ~~aortic~~medical ~~stenosis~~devices ~~patients~~related to transcatheter mitral valve and tricuspid valve regurgitation therapy and granted a limited license to the Company’s related sterilization methods in connection with ~~small~~use ~~aortic~~of ~~annuli~~ADAPT® tissue by 4C in its production of medical devices.

The ~~information~~Supply inAgreement ~~this~~had ~~Current~~a ~~Report~~term expiring on ~~Form~~June ~~8-K~~1, ~~including~~2026, ~~the~~at ~~exhibit~~which ~~attached~~time ~~hereto,~~it iswould ~~being~~automatically ~~furnished~~renew ~~and~~for ~~shall~~successive ~~not~~one-year beterms ~~deemed~~unless toeither beparty ~~filed~~provided ~~for the~~written ~~purposes~~notice of ~~Section~~non-renewal 18180 ofdays ~~the~~prior ~~Securities~~thereto. ~~Exchange~~The ~~Act~~Company ofwill ~~1934~~not ~~(the~~incur ~~“Exchange~~any ~~Act”),~~early ortermination ~~incorporated~~penalties byin ~~reference~~connection ~~into~~with ~~any~~its ~~filing~~non-renewal ~~under~~of the ~~Securities~~Supply ~~Act~~Agreement. ofThe ~~1933~~termination ~~(the~~of ~~“Securities~~this ~~Act”)~~contract ordoes ~~the~~not ~~Exchange~~materially ~~Act,~~impact ~~unless~~on ~~such~~the ~~subsequent~~financial ~~filing specifically~~results ~~references~~of ~~this~~the ~~Current Report on Form 8-K~~Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No.		Description
99.1		ASX announcement: Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Anteris Technologies Global Corp.
Date: November 17, 2025
Date: December 1, 2025	By:	/s/ Wayne Paterson
	By:	/s/ Wayne Paterson
		Name: Wayne Paterson
	Name:	Wayne Paterson
		Title: Vice Chairman and Chief Executive Officer
	Title:	Chief Executive Officer

Filing Compare · Anteris Technologies Global Corp.